Vitamin D and Vitamin D Analogs as Cancer Chemopreventive Agents

Authors

  • Kathryn Z. Guyton PhD, DABT,

    1. Dr. Guyton is with CCS Associates, 2005 Landings Drive, Mountain View, CA 94043, USA.
    Search for more papers by this author
  • Thomas W. Kensler PhD, DABT,

    1. Dr. Kensler is with the Department of Environmental Health Services, Bloomberg School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.
    Search for more papers by this author
  • Gary H. Posner PhD

    1. Dr. Posner is with the Department of Chemistry, School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USA.
    Search for more papers by this author

Abstract

Epidemiologic studies have associated vitamin D, attained through nutrition and sun exposure, with reduced cancer risk. Although dose-limiting hypercalcemia has limited the use of natural vitamin D in cancer prevention, several promising new synthetic vitamin D analogs (deltanoids) are under development. Examples are KH-1060, EB1089, 1 α -hydroxyvitamin D5, vitamin D2, and QW-1624F2-2. Clinical targets for deltanoids include colon, prostate, and breast. Studies to elucidate the molecular mechanisms underlying the observed efficacy of deltanoids are ongoing. The vitamin D receptor, a steroid/thyroid receptor superfamily member, appears to control most deltanoid effects on proliferation, apoptosis, differentiation, and angiogenesis.

Ancillary